Abstracts Archive - Page 1514 of 2607 - ACR Meeting Abstracts

Abstract Number: 1901 • 2017 ACR/ARHP Annual Meeting
Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Samina A. Turk^1,2, Dirkjan van Schaardenburg^3,4, Maarten Boers^4,5, Sylvia de Boer¹, Cindy Fokker¹, Willem F. Lems^4,5 and Michael Nurmohamed^1,5, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: An unfavorable body composition is often present in chronic arthritis patients. This unfavorable composition is a loss of muscle mass (sarcopenia), with a stable…
Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Jon T. Giles¹, Cheilonda Johnson², Elana J. Bernstein³, Erika Darrah⁴, Felipe Andrade⁵ and Sonye K. Danoff⁶, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Columbia University, New York, NY, ⁴Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…
Abstract Number: 1903 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study
Lydia Ho Pui Tam¹, Qing SHANG², Edmund Li³, Priscilla WONG³, Kitty Y Kwok⁴, Emily W Kun⁵, Issac C Yim⁶, Violet KL Lee⁷, Ronald ML Yip⁸, Steve H Pang⁸, Virginia W Lao⁸, Queenie Mak¹, Tsz Ho CHENG¹, Xerox Lau¹, Tena K. Li⁹, Tracy Y. ZHU¹⁰, PW Alex LEE¹ and Lai-Shan Tam², ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ¹⁰Bone Quality and Health Center of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher incidence of cardiovascular disease (CVD) and prevalence of arterial stiffness (AS) due to chronic inflammation. AS…
Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Gerd R. Burmester¹, Joel Kremer², Filip van Den Bosch³, Yihan Li⁴, Yijie Zhou⁴, Ahmed A. Othman⁵, Aileen L. Pangan⁴ and Heidi S. Camp⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Albany Medical College, Albany, NY, ³Rheumatology, Ghent University Hospital, Gent, Belgium, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 1906 • 2017 ACR/ARHP Annual Meeting
Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial
Vibeke Strand¹, Eduardo Mysler², Robert J Moots³, Gene Wallenstein⁴, Ryan DeMasi⁵, Zhen Luo⁶, Koshika Soma⁴, Noriko Iikuni⁷ and Roy Fleischmann⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Shanghai, China, ⁷Pfizer Inc, New York, NY, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient-reported outcomes (PROs) among patients receiving tofacitinib monotherapy,…
Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Nobuyuki Yasuda⁵, Fumitoshi Tago⁶, Makoto Kawakubo⁶, Yasumi Kitahara⁶, Seiichiro Hojo⁶, Tetsu Kawano⁷ and Toshio Imai⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁵KAN Research Institute, Inc., Tokyo, Japan, ⁶Eisai Co., Ltd., Tokyo, Japan, ⁷KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…
Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Carter Thorne¹, Tsutomu Takeuchi², George Karpouzas³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto, Newmarket, ON, Canada, ²Keio University Hospital School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…
Abstract Number: 1909 • 2017 ACR/ARHP Annual Meeting
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Mark C. Genovese¹, Arthur Kavanaugh², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁵, Xiao Ding¹⁵, Pille Harrison¹⁶, Annegret Van der Aa¹⁶, René Westhovens¹⁷ and Rieke Alten¹⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of California, San Diego, La Jolla, CA, ³Oregon Health Sciences University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Vinnitsa Regional Clinical Hospital, Vinnitsa, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Rendelo, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³QUALICLINIC Kft., Budapest, Hungary, ¹⁴Centrum Medyczne AMED Warszawa Targówek, Warszawa, Poland, ¹⁵Gilead Sciences, Inc, Foster City, CA, ¹⁶Galapagos NV, Mechelen, Belgium, ¹⁷KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹⁸Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) currently in Phase 3 development for the treatment of rheumatoid arthritis (RA).…
Abstract Number: 1910 • 2017 ACR/ARHP Annual Meeting
ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis
Tri Tran¹, Tejpal Gill¹, Joshua R. Bennett¹, Vance Holt¹, Sohee Hong², Joel Taurog³ and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institutes of Arthritis and Muskuloskeletal and skin diseases, National Institutes of Health, Bethesda, MD, ³Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Common endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) haplotypes influence the risk of developing axial spondyloarthritis (SpA) in HLA-B27-positive individuals, with loss-of-function and reduced expression…
Abstract Number: 1911 • 2017 ACR/ARHP Annual Meeting
Impaired Control of Autoreactive T Cell Expansion Is Coupled with Type-1 Regulatory T Cell Deficiency in BALB/c ZAP70W163C Mutant Mice
M. Arifur Rahman¹, Daphne Montizaan², Zaied Ahmed Bhuyan³, Linda Rehaume³ and Ranjeny Thomas⁴, ¹The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Australia, ²The University of Groningen, Groningen, Netherlands, ³The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ⁴Dendright Pty Ltd, Brisbane, Australia
Background/Purpose: In the context of reduced TCR signaling in the BALB/c ZAP70W163C mutant (SKG) mouse, development of arthritis, psoriasis-like skin inflammation and ileitis after intra-peritoneal…
Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting
Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Emmerik F.A. Leijten^1,2, Tessa S. van Kempen^1,2, Michel A.M. Olde Nordkamp^1,2, Fleurieke H. Verhagen^2,3, Sanne Hiddingh^2,3, Jonas J.W. Kuiper^2,3, Marianne L. Boes^2,4 and Timothy R.D.J. Radstake^1,2, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…
Abstract Number: 1913 • 2017 ACR/ARHP Annual Meeting
Inter-Omic Analysis Reveals Functional Relationship between Diverse Gut Microbiota and Dysregulated Host Immune Response in HLA-B27-Mediated Experimental Spondyloarthritis
Tejpal Gill¹, Stephen R. Brooks², Mark Asquith³, James T. Rosenbaum⁴ and Robert Colbert⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ³Oregon Health & Science University, Portland, OR, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵NIAMS/NIH, Bethesda, MD
Background/Purpose: HLA-B27 has been hypothesized to alter gut microbiota and host-microbe interactions to promote spondyloarthritis (SpA). In HLA-B27 transgenic (HLA-B27 Tg) rats with experimental SpA,…
Abstract Number: 1914 • 2017 ACR/ARHP Annual Meeting
Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease
Zoya Qaiyum^1,2, Eric Gracey^3,4, Yuchen Yao^3,4 and Robert D Inman⁵, ¹Genetics and Development, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Immunology, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Immunology and Institute of Medical Science, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing spondylitis (AS) has a strong connection with gut inflammation: 10% of AS patients have inflammatory bowel disease (IBD) and 60% have subclinical ileal…
Abstract Number: 1915 • 2017 ACR/ARHP Annual Meeting
Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation
Karlijn Debusschere¹, Heleen Cypers², Peggy Jacques³, Filip van Den Bosch⁴, Thomas Renson⁵, Don Souza⁶, Martha Brown⁶, Gerald Nabozny⁷, Devin Dove⁶, Alexander Klimowicz⁸ and Dirk Elewaut⁹, ¹Ghent University - VIB, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Rheumatology, Ghent University Hospital, Gent, Belgium, ⁵Rheumatology, Ghent University Hospital, GENT, Belgium, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁸Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁹VIB Inflammation Research Center, University of Ghent, Ghent, Belgium
Background/Purpose: An intruiging link exists between gut and joint inflammation in spondyloarthritis (SpA). About 50% of patients has subclinical (eg. microscopic) gut inflammation, which represents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].